Pfizer general counsel is out

Share this article:

Pfizer's general counsel Amy Schulman is leaving the company. The drugmaker announced Tuesday that Schulman, who was supposed to head up the company's vaccines and oncology division, will not step into the role and is leaving her positions both as general counsel and as part of the company's executive leadership team.

Instead, Albert Bourla will be group president of the vaccines, oncology and consumer healthcare business when it becomes an official financial entity within Pfizer in 2014. Susan Silbermann has been named president of the global vaccines business. Titles for Bourla and Silbermann go into effect next year.

The company said Schulman's departure was part of a mutual agreement.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.